Immatics/IMTX

$12.94

3.43%
-
1D1W1MYTD1YMAX

About Immatics

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Ticker

IMTX

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Harpreet Singh

Employees

210

Headquarters

Tuebingen, Germany

Immatics Metrics

BasicAdvanced
$1.28B
Market cap
-
P/E ratio
-$1.15
EPS
0.69
Beta
-
Dividend rate

What the Analysts think about Immatics

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
48.07% upside
High $25.01
Low $14.01
$12.94
Current price
$19.16
Average price target

Immatics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-447.45% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
€5.9M
-73.54%
Net income
€-26.4M
7.32%
Profit margin
-447.45%
305.63%

Immatics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.52%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-€0.23
-€0.26
-€0.32
-€0.32
-
Expected
-€0.17
-€0.27
-€0.25
-€0.36
-€0.32
Surprise
35.29%
-4.29%
30.08%
-11.52%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Immatics stock

Buy or sell Immatics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing